News from cytrx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Aug 10, 2020, 08:00 ET CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
CytRx Corporation (OTCQB: CYTR), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative...
Jul 21, 2020, 09:00 ET CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Jul 20, 2020, 09:00 ET CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson's Disease Research
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Jun 29, 2020, 09:00 ET CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Jun 01, 2020, 09:00 ET CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
May 26, 2020, 09:00 ET CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
May 21, 2020, 09:00 ET CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Apr 29, 2020, 09:00 ET CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Mar 10, 2020, 09:00 ET CytRx Corporation Provides Update on Management Change
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Feb 28, 2020, 09:00 ET CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Feb 11, 2020, 09:00 ET CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Feb 04, 2020, 09:00 ET CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative...
Jan 29, 2020, 09:00 ET CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted that ImmunityBio, previously NantCell, Inc., ...
Dec 19, 2019, 09:00 ET CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted Orphazyme A/S received FDA Breakthrough...
Aug 09, 2019, 09:00 ET CytRx Corporation Reports Second Quarter 2019 Financial Results
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today announced...
Jul 30, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted...
Jul 22, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol...
Jun 26, 2019, 09:00 ET CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been...
Jun 19, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that...
May 31, 2019, 09:00 ET CytRx Corporation to Commence Trading on OTCQB Venture Market
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will...
May 15, 2019, 09:00 ET CytRx Corporation Reports First Quarter 2019 Financial Results
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...
May 08, 2019, 09:00 ET CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been...
May 02, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that...
Apr 29, 2019, 09:00 ET CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol...
Mar 29, 2019, 09:00 ET CytRx Corporation Reports 2018 Financial Results
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...
